Additional Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs
Pub. online: 1 July 2025
Type: Research Communication
Open Access
Open Access
Area: Cancer Research
Accepted
24 May 2025
24 May 2025
Published
1 July 2025
1 July 2025
References
Cao, S. and Pan, J. (2025). Comments on “Considerations for Single-Arm Trials in Oncology Drug Accelerated Approval”. The New England Journal of Statistics in Data Science.
Lu, F., Wang, T., Lu, Y. and Chen, J. (2025). Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs. The New England Journal of Statistics in Data Science 3(1) 16–27.
Smith, G. C. and Pell, J. P. (2003). Parachute use to prevent death and major trauma related to gravitational challenge: sys-tematic review of randomised controlled trials. BMJ 327(7429) 1459–1461.
Chawla, S. P., Pang, S. S., Jain, D., Jeffrey, S., Chawla, N. S., Song, P. Y., Hall, F. L. and Gordon, E. M. (2025). Gene and Cell Therapy for Sarcomas: A Review. Cancers 17(7) 1125.
Gray, C., Ralphs, E., Fox, M. P., Lash, T. L., Liu, G., Kou, T. D., Rivera, D. R., Bosco, J., Braun, K. V. N., Grimson, F. et al. (2024). Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls. Pharmacoepidemiology and drug safety 33(5) 5796.
Gupta, A., Hsu, G., Kent, S., Duffield, S. J., Merinopoulou, E., Lockhart, A., Arora, P., Ray, J., Wilkinson, S. and Scheuer, N. (2025). Quantitative Bias Analysis for Single-ArmTrials With External Control Arms. JAMA Network Open 8(3) 252152–252152.
Ding, P., Fang, Y., Faries, D., Gruber, S., Lee, H., Lee, J. -Y., Mishra-Kalyani, P., Shan, M., van der Laan, M., Yang, S. et al. (2024). Sensitivity Analysis for Unmeasured Confounding inMedical Product Development and Evaluation Using Real WorldEvidence. arXiv preprint arXiv:2307.07442.
Ho, M., Gruber, S., Fang, Y., Faris, D. E., Mishra-Kalyani, P., Benkeser, D. and van der Laan, M. (2024). Examples ofapplying RWE causal-inference roadmap to clinical studies. Statistics in Biopharmaceutical Research 16(1) 26–39.
Hashmi, M., Rassen, J. and Schneeweiss, S. (2021). Single-armoncology trials and the nature of external controls arms. Journal of Comparative Effectiveness Research 10(12) 1053–1066.
Mishra-Kalyani, P., Kordestani, L. A., Rivera, D., Singh, H., Ibrahim, A., DeClaro, R., Shen, Y., Tang, S., Sridhara, R. and Kluetz, P. (2022). External control arms in oncology:current use and future directions. Annals of Oncology 33(4) 376–383.
Chen, J., Scharfstein, D., Wang, H., Yu, B., Song, Y., He, W., Scott, J., Lin, X. and Lee, H. (2024). Estimands in Real-WorldEvidence Studies. Statistics in Biopharmaceutical Research 16(2) 257–269.
Levenson, M., He, W., Chen, L., Dharmarajan, S., Izem, R., Meng, Z., Pang, H. and Rockhold, F. (2023). Statistical Con-sideration for Fit-for-Use Real-World Data to Support RegulatoryDecision Making in Drug Development. Statistics in Biopharmaceutical Research 15(3) 689–696.
Gruber, S., Lee, H., Phillips, R., Ho, M. and van der Laan, M. (2023). Developing a Targeted Learning-based statistical anal-ysis plan. Statistics in Biopharmaceutical Research 15(3) 468–475.
Mittal, A., Kim, M. S., Dunn, S., Wright, K. and Gyawali, B. (2024). Frequently asked questions on surrogate endpoints inoncology—opportunities, pitfalls, and the way forward. EClinicalMedicine: Part of The Lancet Discovery Science.
Liu, L., Choi, J., Musoro, J. Z., Sauerbrei, W., Amdal, C. D., Alanya, A., Barbachano, Y., Cappelleri, J. C., Falk, R. S. and Fiero, M. H. (2023). Single-arm studies involving patient-reported outcome data in oncology: a literature review on currentpractice. The Lancet Oncology 24(5) 197–206.
Di Maio, M. (2023). The value of patient-reported outcomes insingle-arm cancer trials. Cancer Investigation 41(5) 491–494.
Gupta, M., Akhtar, O. S., Bahl, B., Mier-Hicks, A., Attwood, K., Catalfamo, K., Gyawali, B. and Torka, P. (2024). Health-related quality of life outcomes reporting associ-ated with FDA approvals in haematology and oncology. BMJ Oncology 3(1) 000369.
Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R. and Pang, L. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable ormetastatic urothelial cancer (KEYNOTE-052): a multicentre,single-arm, phase 2 study. The Lancet Oncology 18(11) 1483–1492.
Oda, Y. and Narukawa, M. (2022). Response rate of anticancerdrugs approved by the Food and Drug Administration based ona single-arm trial. BMC Cancer 22(1) 277.
Yao, S., Shang, Q., Ouyang, M., Zhou, H., Yao, Z., Liu, Y. and Luo, S. (2025). Designing Single-Arm Clinical Trials: Prin-ciples, Applications, and Methodological Considerations. Annals of Clinical Epidemiology 25011.
O’Malley, A. J., Normand, S. q. L. T. and Kuntz, R. E. (2002). Sample size calculation for a historically controlled clinicaltrial with adjustment for covariates. Journal of Biopharmaceutical Statistics 12(2) 227–247.
Englert, S. and Kieser, M. (2012). Adaptive designs for single-arm phase II trials in oncology. Pharmaceutical Statistics 11(3) 241–249.
Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D. and Neuenschwander, B. (2014). Robustmeta-analytic-predictive priors in clinical trials with historicalcontrol information. Biometrics 70(4) 1023–1032. https://doi.org/10.1111/biom.12242. MR3295763
Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N. and Lindborg, S. (2014). Use of historical control data for assessingtreatment effects in clinical trials. Pharmaceutical Statistics 13(1) 41–54.
Rahman, R. and Iftakhar Alam, M. (2022). Stopping for ef-ficacy in single-arm phase II clinical trials. Journal of Applied Statistics 49(10) 2447–2466. https://doi.org/10.1080/02664763.2021.1904846. MR4440947
Seeger, J. D., Davis, K. J., Iannacone, M. R., Zhou, W., Dreyer, N., Winterstein, A. G., Santanello, N., Gertz, B. and Berlin, J. A. (2020). Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. Pharmacoepidemiology and Drug Safety 29(11) 1382–1392.
Rippin, G., Ballarini, N., Sanz, H., Largent, J., Quinten, C. and Pignatti, F. (2022). A review of causal inference for external comparator arm studies. Drug Safety 45(8) 815–837.
Yue, L. Q., Lu, N. and Xu, Y. (2014). Designing premarket observational comparative studies using existing data as controls: challenges and opportunities. Journal of Biopharmaceutical Statistics 24(5) 994–1010. https://doi.org/10.1080/10543406.2014.926367. MR3246540
Chen, J., Ho, M., Lee, K., Song, Y., Fang, Y., Goldstein, B. A., He, W., Irony, T., Jiang, Q. and van der Laan, M. (2023). The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. Statistics in Biopharmaceutical Research 15(1) 29–42.
